MedTrace Logo

Effect of the Known Antihypertensive Drug Telmisartan on Red Blood Cells and Circulation in the Smallest Blood Vessels

NCT00559286 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-01-29

No results posted yet for this study

Summary

The hypothesis of the presented study is: Telmisartan induces an increase of eNOS activity in RBC resulting in an enhanced intravascular NO bioavailability, an ameliorated RBC deformability and a reduction of RBC and platelet aggregation. This could be a potential mechanism of the improvement of microcirculatory disorders, especially in patients with diabetes mellitus and arterial hypertension, treated with Telmisartan.

Conditions

  • Arterial Hypertension
  • Diabetes Mellitus Type 2 IRC or NIR

Interventions

DRUG

Telmisartan

application of 80mg or 20mg Telmisartan per day for 30 days

Sponsors & Collaborators

  • CTCA

    collaborator UNKNOWN

  • Heidelberg University

    collaborator OTHER

  • Bayer

    collaborator INDUSTRY

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Malte Kelm, MD, Univ.Prof. · Department of Cardiology, Angiology, Pulmonary Diseases and cardiologic critical care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00559286 on ClinicalTrials.gov